Plain-English translation of NCT06436677 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is looking at a new approach to treating cutaneous T-cell lymphoma — a type of blood cancer that affects the skin. Instead of using a one-size-fits-all treatment, researchers will analyze the molecular characteristics of your skin lesions to create a personalized treatment plan designed specifically for your type of lymphoma. The goal is to see if this personalized approach helps patients live longer and have better quality of life.
Many patients with cutaneous T-cell lymphoma don't respond well to standard skin-focused treatments alone. This study exists to see if understanding the unique molecular makeup of each patient's cancer — and using that information to choose treatments — can lead to better results and longer-lasting remissions.
You likely qualify if…
You likely don't qualify if…
If you join this study, researchers will take a small skin sample from your lymphoma lesions and analyze it to determine your cancer's molecular subtype. Based on these results, you'll be assigned a personalized treatment strategy. You'll then receive follow-up care and monitoring to track how well the treatment works, with visits to one of the three participating hospitals in Beijing. The study compares your outcomes to historical data from similar patients treated before, so you'll be helping researchers understand whether this personalized approach truly improves survival and quality of life.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China